OTC Markets OTCPK - Delayed Quote USD

BioVaxys Technology Corp. (BVAXF)

0.0612

+0.0012

(+2.00%)

At close: 3:54 PM EDT

BioVaxys Technology Corp. Announces Failure to File Cease Trade Order

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the "Company") announces that the Ontario Securities Commission (the "OSC") has issued a failure to file cease trade order ("FFCTO") under National Policy 11-207 Failure-to-File Cease Trade Orders and Revocations in Multiple Jurisdictions ("NP 11-207"), prohibiting the trading by any person of any securities of the Company in Canada, including trades in the Company's common shares made through the Canadian Securities Exchange.

PR Newswire 12 days ago

BVAXF
+2.00%
BioVaxys Technology Corp. Closes SECOND Tranche of Private Placement

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (the "Company") is pleased to announce that it has closed the second tranche (the "Second Tranche") of its previously announced non-brokered private placement (the "Private Placement") with the issuance of 4,301,923 units (the "Units") of the Company at a price of $0.065 per Unit for aggregate gross proceeds of $279,625.00.

CNW Group 18 days ago

BVAXF
+2.00%
BioVaxys Technology Corp. Closes First Tranche of Private Placement

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (the "Company") is pleased to announce that it has closed the first tranche (the "First Tranche") of its previously announced non-brokered private placement (the "Private Placement") with the issuance of 5,126,574 units (the "Units") of the Company at a price of $0.065 per Unit for aggregate gross proceeds of $333,227.31.

CNW Group 25 days ago

BVAXF
+2.00%
BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the "Company") is providing this bi-weekly update on the status of the management cease trade order granted on February 29, 2024 (the "MCTO"), by its principal regulator, the Ontario Securities Commission (the "OSC"), under National Policy 12-203 - Management Cease Trade Orders ("NP 12-203"), following the Company's announcement on February 21, 2024 (the "Default Announcement"), that it was unable to file its audited annual financi

CNW Group 26 days ago

BVAXF
+2.00%
BIOVAXYS APPOINTS CHRISTOPHER CHERRY AS CHIEF FINANCIAL OFFICER

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the "Company") is pleased to announce that it has appointed Christopher Cherry as Chief Financial Officer. Mr. Cherry, a Chartered Accountant and Certified Public Accountant, has extensive experience, having served as a CFO of many public issuers in a broad range of sectors. Mr. Cherry responsibilities will include full cycle accounting, supervision and planning, financial statement preparation, management discussion and analysis (

PR Newswire 28 days ago

BVAXF
+2.00%
BIOVAXYS AND SPAYVAC-FOR-WILDLIFE, INC. ANNOUNCE LAUNCH OF FIELD TRIAL FOR LARGE-SCALE IMMUNOCONTRACEPTION IN THE COMMERCIAL AQUATIC FARMING INDUSTRY

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys") and SpayVac-for-Wildlife, Inc. ("SpayVac") jointly announce that SpayVac has partnered with a world leader in the aquaculture space to field test single-injection, long-lasting immuno-contraceptive vaccines in farmed rainbow trout.

PR Newswire last month

BVAXF
+2.00%
BioVaxys Announces Allowance of DPX Formulation Patent for the United States and Filing of Additional International Patent Applications for Phase 1 DPX SurMAGE

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") announced that it has received a Notice of Allowance from the United States Patent and Trademark Office ("USPTO") for a Patent ("Patent") for inducing an antibody immune response from a low dose volume delivery of a B-cell epitope formulated with DPX™. Part of the extensive Intellectual Property portfolio acquired by BioVaxys from the former IMV, Inc, this Patent was recently allowed in Japan and is current

PR Newswire last month

BVAXF
+2.00%
BIOVAXYS ANNOUNCES PLANNED PRIVATE PLACEMENT

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "the Company") announces that it intends to complete a non-brokered private placement (the "Private Placement") consisting of up to 15,384,615 units ("Units") at a price of $0.065 per Unit for total gross proceeds of up to CAD$1,000,000, before deducting any offering-related expenses. Each Unit consists of one common share (a "Common Share") and one whole Common Share purchase warrant (a "Warrant"). Each Warrant is ex

CNW Group 2 months ago

BVAXF
+2.00%
BioVaxys Technology Corp. Granted Voluntary Management Cease Trade Order

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the "Company") today announced that the Ontario Securities Commission (the "OSC"), as the Company's principal regulator, on February 29, 2024, granted the Company's previously announced application for the imposition of a management cease trade order under National Policy 12-203 – Management Cease Trade Orders ("NP 12-203").

CNW Group 2 months ago

BVAXF
+2.00%
BioVaxys Announces Allowance of DPX-Related Patent for Japan and Filing of Additional International Patent Applications

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") announced that it has received a Notice of Allowance from the Japanese Patent Office for a Patent ("Patent") for inducing an antibody immune response from a low dose volume delivery of a B-cell epitope formulated with DPX™. This Patent was part of the extensive Intellectual Property portfolio recently acquired by BioVaxys from the former IMV, Inc. This Patent has already been issued in the US, and is curren

CNW Group 2 months ago

BVAXF
+2.00%
Annual Financial Statements Update for the Year Ended October 31, 2023

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") announces that as a result of delays in the completion of its audit, the Company anticipates that it will experience a short term delay in filing its audited annual financial statements for the year ended October 31, 2023, its management's discussion and analysis of financial statements for the year ended October 31, 2023, its annual information form for the year ended October 31, 2023 and related filings (

CNW Group 3 months ago

BVAXF
+2.00%
BIOVAXYS COMPLETES THE ACQUISITION OF ALL INTELLECTUAL PROPERTY, IMMUNOTHERAPEUTICS PLATFORM TECHNOLOGY, AND CLINICAL STAGE ASSETS OF THE FORMER IMV INC.

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") is pleased to announce has completed the acquisition of the entire portfolio of discovery, preclinical and clinical development stage assets of former Canadian biotechnology company, IMV Inc., Immunovaccine Technologies Inc., and IMV USA ("IMV"). On February 11th, 2024, the Company executed the definitive Asset Purchase Agreement for the extensive technology portfolio from HIMV, LLC, an acquisition vehicle

CNW Group 3 months ago

BVAXF
+2.00%
BioVaxys Acquires All Intellectual Property, Immunotherapeutics Platform Technology, and Clinical Stage Assets of the Former IMV Inc.

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") announced that it has executed the definitive Asset Purchase Agreement dated February 11th, 2024 to acquire the entire portfolio of discovery, preclinical and clinical development stage assets in oncology, infectious disease, antigen desensitization, and other immunological fields based on the DPX™ immune educating platform technology, developed by Canadian biotechnology company, IMV Inc., Immunovaccine Tec

PR Newswire 3 months ago

BVAXF
+2.00%
BIOVAXYS ANNOUNCES COMPLETION OF FINAL TRANCHE OF PRIVATE PLACEMENT

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") announces that it has completed the final tranche of a non-brokered private placement (the "Private Placement") consisting of 16,716,666 ("Units") at a price of $0.03 per Unit for total gross proceeds of $501,500. Each Unit consists of one common share (a "Common Share") and one whole Common Share purchase warrant (a "Warrant"). Each Warrant is exercisable for one additional Common Share at an exercise

CNW Group 3 months ago

BVAXF
+2.00%
BIOVAXYS ANNOUNCES COMPLETION OF FIRST TRANCHE OF PRIVATE PLACEMENT

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") announces that it has completed the first tranche of a non-brokered private placement (the "Private Placement") consisting of 36,783,334 ("Units") at a price of $0.03 per Unit for total gross proceeds of $1,103,500. Each Unit consists of one common share (a "Common Share") and one whole Common Share purchase warrant (a "Warrant"). Each Warrant is exercisable for one additional Common Share at an exercis

CNW Group 3 months ago

BVAXF
+2.00%
BIOVAXYS ANNOUNCES COMPLETED DEBT SETTLEMENT

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") announces that it completed the settlement of CAD$215,000 in debt through the issuance of 7,166,666 common shares issued at a deemed price of $0.03 per common share. None of the debt settled included accrued salaries to officers or directors of the Company, nor does it include payments for Investor Relations Activities. The debt included the participation of certain related parties, including BioVaxys C

PR Newswire 3 months ago

BVAXF
+2.00%
BioVaxys Executes Letter of Intent for Major Immunotherapeutics Technology Acquisition

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") announced today that it has executed a non-binding Letter of Intent ("LOI") to acquire the core platform technology and entire immunotherapeutics intellectual property portfolio of discovery, preclinical development, and Phase II clinical study stage assets in oncology and other immunological fields, including active licenses with several pharma companies, formerly owned by an unnamed biotechnology company

CNW Group 5 months ago

BVAXF
+2.00%
BioVaxys and Procare Health Agree to Termination of USA Distribution Agreement for Papilocare

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") announced today that as part of BioVaxys' efforts to refocus on immunotherapeutics, Biovaxys and Procare Health ("Procare") have jointly and amicably agreed to terminate the US Distribution Agreement for Papilocare and Immunocaps.

CNW Group 5 months ago

BVAXF
+2.00%
BioVaxys in Non-Binding Discussions for Major Immunotherapeutics Technology Acquisition

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") announced today that it is in non-binding discussions to acquire an immunotherapeutics intellectual property portfolio of discovery, preclinical and clinical development stage assets in oncology and other immunological fields formerly owned by an unnamed biotechnology company and now held by the secured creditor. At this time, no formal agreement is in place.

PR Newswire 5 months ago

BVAXF
+2.00%
BioVaxys and The Ohio State University Extend Research Collaboration

BioVaxys Technology Corp. (CSE: BIOV) (OTCQB: BVAXF) (5LB: FRA) ("BioVaxys" or "the Company"), is pleased to announce that it has further extended its research collaboration with The Ohio State University ("The Ohio State") for SARS-CoV-2, SARS-CoV-1, and pan-sarbecovirus vaccine research. This is the second twelve-month extension of the research collaboration between BioVaxys and the University since 2021.

CNW Group 8 months ago

BVAXF
+2.00%
FRA

Performance Overview

Return	BVAXF	S&P/TSX Composite index
YTD	+49.27%	+6.23%
1-Year	+137.21%	+11.77%
3-Year	-67.27%	+12.60%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

BioVaxys Technology Corp. (BVAXF)

BioVaxys Technology Corp. Announces Failure to File Cease Trade Order

BioVaxys Technology Corp. Closes SECOND Tranche of Private Placement

BioVaxys Technology Corp. Closes First Tranche of Private Placement

BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update

BIOVAXYS APPOINTS CHRISTOPHER CHERRY AS CHIEF FINANCIAL OFFICER

BIOVAXYS AND SPAYVAC-FOR-WILDLIFE, INC. ANNOUNCE LAUNCH OF FIELD TRIAL FOR LARGE-SCALE IMMUNOCONTRACEPTION IN THE COMMERCIAL AQUATIC FARMING INDUSTRY

BioVaxys Announces Allowance of DPX Formulation Patent for the United States and Filing of Additional International Patent Applications for Phase 1 DPX SurMAGE

BIOVAXYS ANNOUNCES PLANNED PRIVATE PLACEMENT

BioVaxys Technology Corp. Granted Voluntary Management Cease Trade Order

BioVaxys Announces Allowance of DPX-Related Patent for Japan and Filing of Additional International Patent Applications

Annual Financial Statements Update for the Year Ended October 31, 2023

BIOVAXYS COMPLETES THE ACQUISITION OF ALL INTELLECTUAL PROPERTY, IMMUNOTHERAPEUTICS PLATFORM TECHNOLOGY, AND CLINICAL STAGE ASSETS OF THE FORMER IMV INC.

BioVaxys Acquires All Intellectual Property, Immunotherapeutics Platform Technology, and Clinical Stage Assets of the Former IMV Inc.

BIOVAXYS ANNOUNCES COMPLETION OF FINAL TRANCHE OF PRIVATE PLACEMENT

BIOVAXYS ANNOUNCES COMPLETION OF FIRST TRANCHE OF PRIVATE PLACEMENT

BIOVAXYS ANNOUNCES COMPLETED DEBT SETTLEMENT

BioVaxys Executes Letter of Intent for Major Immunotherapeutics Technology Acquisition

BioVaxys and Procare Health Agree to Termination of USA Distribution Agreement for Papilocare

BioVaxys in Non-Binding Discussions for Major Immunotherapeutics Technology Acquisition

BioVaxys and The Ohio State University Extend Research Collaboration

Performance Overview